Tenderwize
Retour à la recherche

Adalimumab Discount Contract

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 337 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

15 / 100

Facteurs de risque

No estimated value or guaranteed volume; revenue depends on actual prescriptions and discounts.

Structured data indicates EU-funded, but XML notice states no EU funds. This may affect audit requirements.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Conclusion of discount contracts for Adalimumab
  • 24-month term from 01.08.2025 to 31.07.2027
Afficher le résumé complet

Open-house procedure by Techniker Krankenkasse and participating health insurances for discount contracts on Adalimumab (pharmaceutical product) under §130a Abs. 8 SGB V. Contracts are concluded with any eligible pharmaceutical entrepreneur on standard terms, without exclusivity. Term: 01.08.2025 – 31.07.2027 (24 months). No estimated value provided. No competitive award; eligibility criteria must be met.

Risques

No estimated value or guaranteed volume; revenue depends on actual prescriptions and discounts.

Structured data indicates EU-funded, but XML notice states no EU funds. This may affect audit requirements.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG
  • Must hold a valid marketing authorization for Adalimumab or be entitled to market it
  • Must have seat in Germany, EU, or EEA

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria defined; acceptance based on eligibility.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Adalimumab Discount Contract

Conclusion of discount contracts for the active ingredient Adalimumab under an open-house procedure. No exclusivity, standard conditions.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria defined; acceptance based on eligibility.

Date limite

Deadline Jul 30, 2027

Détails de la procédure

Date de publication
12 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
382585-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3